Pub. Date : 2020 Apr
PMID : 31732977
2 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | A major revolution in the treatment of chronic lymphocytic leukemia (CLL) began with the approval of ibrutinib, a first-in-class oral inhibitor of Bruton tyrosine kinase (BTK), for the treatment of relapsed/refractory (R/R) and/or TP53 mutated patients with CLL. | ibrutinib | tumor protein p53 | Homo sapiens |
| 2 | A possible strategy to overcome some of these obstacles is to combine ibrutinib with other targeted agents especially in high-risk disease, such as previously treated refractory patients or those with TP53 aberrations or complex karyotypes, in whom rapid eradication of disease is most desirable. | ibrutinib | tumor protein p53 | Homo sapiens |